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Abstract
Tau is a microtubule-associated protein, which is highly expressed in the central nervous system as
well as ocular neurons and stabilizes microtubule structure. It is a phospho-protein being moderately
phosphorylated under physiological conditions but its abnormal hyperphosphorylation or some post-
phosphorylation modifications would result in a pathogenic condition, microtubule dissociation, and aggre-
gation. The aggregates can induce neuroinflammation and trigger some pathogenic cascades, leading to
neurodegeneration. Taking these together, targeting pathogenic tau employing tau immunotherapy may
be a promising therapeutic strategy in fighting with cerebral and ocular neurodegenerative disorders.
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Tau is a microtubule (MT)-associated protein and
the most common unfolded protein upon neu-
rodegenerative disorders, which was described
in 1975 by Weingarten and colleagues.[1] This
protein gene encoding (MAPT), being located at
chromosome 17q21,[2] is predominantly expressed
in various regions of the human brain, mostly
in neurons and to a lesser degree in astrocytes
and oligodendrocytes.[3, 4]Tau is an axonal protein,
binds to MTs by its MT-binding domain, stabilizing
microtubule structure and the cytoskeleton.[5–7]
Other functions of tau are their roles in cargo con-
veyance and signaling pathways.[8, 9] Tau aggre-
gation is widely accepted as a pathological pro-
cess in central nervous system (CNS), leading to
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neurodegenerative disorders such as: Alzheimer
disease (AD) and post-traumatic brain injuries[10].
Since ocular neurodegeneration is similar to CNS
neurodegenerative disorders, there are several
evidences that pathogenic forms of tau are prone
to aggregation and responsible for retinal degen-
eration in the subjects with ocular neurodegener-
ation, such as age-related macular degeneration
(AMD) and glaucoma.[11–13] With this in mind, we
aimed to summarize scientific reports focusing
on the role of tauopathy in the pathogenesis of
neurodegenerative diseases, in particular in the
eye, and to explain the role of targeted therapy as a
promising therapeutic modality for pathogenic tau
aggregations.
Tau Gene
The MAPT gene include 16 exons, of which 11
are expressed in the human brain and 6 main
isoforms of 37-46 kDa tau mRNA are produced
by alternative splicing that results in production of
six tau protein isoforms. Difference between the
isoforms is dependent on the N-terminal region
where the number of copies of a repeated motif
consisting of 29-amino acids (0N, 1N, or 2N), and
the C-terminus including either three (3R tau) or
four (4R tau) MT-binding repeats.[14–16] In human
CNS, the longest tau isoform with 441 amino
acids, 2N4R, has 80 Thr and Ser residues that
can be modified by numerous kinases[18] and a
low proportion of hydrophobic amino acids, which
renders tau a hydrophilic protein.[17]
Differential splicing that alters tau protein iso-
form expression occurs at every step of develop-
ment and neuronal maturation.[10] In the adult brain,
all six tau isoforms are expressed, in contrast to
fetal brain where the shortest tau isoform (0N3R)
is expressed.[16] In the cerebral cortex of healthy
adults, approximately equal amounts of 3R and 4R
tau isoforms are expressed.[16] Additionally, it has
been reported that there is 3R/4R ratio changes
in the AD patient brains compared to the healthy
subjects, demonstrating that the isoforms ratio
is a determinant factor in tau pathogenicity and
aggregation.
Regional splicing of tau mRNA has also been
observed in human brain. The expression rate of
0N3R tau isoform in the cerebellum is lower than
other regions in human brain and 4R tau isoforms
are highly expressed in the globus pallidus.[19, 20]
Tau Protein Structure
Tau protein has a flexible conformation with a
low level of secondary structure[21, 22] and is subdi-
vided into four domains with different biochemical
properties. The N-terminal acidic domain with 1–
150 amino acids includes two N-terminal inserts.
Tau protein amino acids 151–243 are known as
the proline-rich domain.[6] The MT-binding domain
of tau consists of four repeated motifs that are
separated from each other by flanking regions,
which altogether provide a structure by which the
tau can bind to and stabilizeMTs.[22, 23] Amino acids
370–441 are known as the C-terminal region.[22]
The N-terminal domain protrudes out of the
MT surface, and although this domain does not
bind directly to MTs, it has a role in MT assembly
regulation and affects the attachment or spacing
between MTs and other components in the cell.[24]
The N-terminal inserts affect the distribution of tau
molecules in the cell; it was demonstrated that
each tau isoform (0N, 1N, and 2N) has different
subcellular localizations in the mouse brain.[25] In
addition, tau, via interacting with the membrane
binding protein annexin A2, interacts with the
plasma membrane by its N-terminal domain.[26, 27]
The N-terminal domain can also bind to the C-
terminus of p150 in dynactin protein, which has an
essential role in the connection between dynein
and cargoes.[28] Moreover, tau isoforms have dis-
tinct protein interaction patterns; for instance,
apolipoprotein A1 can bind to 2N tau isoforms;
however, synaptophysin and β-synuclein attach to
0N tau isoforms.[29]
The proline-rich domain of tau has several
recognition sites for attaching Src homology-3
(SH3)-containing proteins such as the Src family
of protein kinases (Lck, Fgr, and Fyn), the p85α
regulatory subunit of phosphatidylinositol 3-kinase
(PI3K), bridging integrator 1 (Bin1), phospholipase
C (PLC), γ1, PLCγ2, growth factor receptor bound
protein 2, and peptidylprolyl cis/trans isomerases
NIMA-interacting 1.[30] Tau interactions with SH3-
containing proteins play an important role in mod-
ulating the signaling functions of tau. Additionally,
signaling pathways are associated with the acti-
vation of phosphatidylinositol and phosphatidyli-
nositol bisphosphate, which collaborate with the
tau proline-rich domain.[31, 32] Furthermore, the tau
proline-rich domain acts as a DNA and RNA
recognition site.[33, 34] This domain also has an
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important role in the inter MT spacing and intra-
cellular trafficking[35, 36] as well as actin binding,[37]
highlighting an important role in neuronal cell
signaling and neuronal plasticity.
Tau Post-translational Modifications
Although several post-translational modifications,
in forms of phosphorylation, acetylation, glyca-
tion, cleavage or truncation, prolyl-isomerization,
polyamination, nitration, ubiquitination, oxidation,
and sumoylation have been identified to modulate
tau protein,[38–40] the most well-known is phos-
phorylation in which the abnormal hyperphospho-
rylation is associated with tauopathy.[41] Although
phosphorylation is an essential tau modifier under
physiological conditions,[1] abnormal phosphoryla-
tion or hyperphosphorylation are other modifiers
by which tau gets prone to aggregation.[42, 43]
For instance, hyperphosphorylated tau forms the
oligomers and neurofibrillary tangles (NFTs) that
exert toxic effects on neuronal function and AD
progression.[44]
Although 15–30 phosphorylation sites, that
mostly corresponded to proline-directed sites
in the proline-rich domain of tau were discov-
ered in tau protein,[45] increased phosphorylation,
especially at the MT-binding domains, has also
been demonstrated in association with increased
MT dynamicity and reduced levels of neuronal
excitability in the early stages of AD.[46]
Threonine175 (Thr175) is one of the important
phosphorylation sites in tau protein that was
first identified in AD[47] and then in amyotrophic
lateral sclerosis (ALS) with cognitive impairment
(ALSci).[48–52] This modification site can be phos-
phorylated by multiple kinases related to tauopa-
thy, including GSK3β, JNK, ERK2, and p38,[53] that
induce tau aggregation.[54] pThr175 tau induces
GSK3β activation and can augment tau phospho-
rylation at Thr231 and other residues. This results in
dissociation of tau from MTs, self-aggregation, and
neuronal toxicity.[55]
Threonine231 (Thr231) is another important phos-
phorylation site in tau protein that is phosphory-
lated or hyperphosphorylated in the cerebrospinal
fluid of AD patients, and is correlated with memory
loss and progression of AD from mild to severe
cognitive impairments.[56]
Tau hyperphosphorylation may result from
downregulation of phosphatases, especially
protein phosphatase 2A by okadaic acid (OA).[57]
It was shown that OA treatment induced
phosphorylation of tau at Ser202 and Ser396 in
cultivated neuroblastoma cells.[58]
Cystatin C (CysC) is a cysteine protease inhibitor
of cathepsin family, lysosomal proteases, that is
widely expressed in various cells and tissues.[59]
CysC protein and its gene are upregulated in
AD brains, posing a risk factor for late-onset
AD.[60, 61] CysC does not affect production of
cellular amyloid beta peptide (Aβ); however,
overexpression of CysC in neurons leads to
inhibition of GSK3β turnover, augmentation of
GSK3β levels in neurons that promotes GSK3β-
tau phosphorylation at Ser396/404, MT instability, and
neurodegeneration.[62, 63]
GSK3β is one of the kinases having an important
role in NFT formation and dystrophic neurites by
tau phosphorylation in the brain.[64–67] High activity
of GSK3β can be detected in the frontal cortex[68]
and hippocampus of AD patients.[65] It is notable
that Lithium, as a potent GSK3β inhibitor, is being
widely prescribed for neurodegenerative disorders
such as AD.
Cyclin-dependent kinase 5 (Cdk5) is a proline-
directed Ser/Thre kinase, that can phosphorylate
tau at several Ser-Pro and Thre-Pro motifs. Phos-
phorylation at these residues affects MT stability
via dissociation of tau from MTs. Cdk5 is highly
expressed in axons and growth cones serving to
induce neurite outgrowth and cell migration.[69]
Peptidyl-prolyl cis-trans isomerase NIMA-
interacting 1 (Pin1), a phospho-Ser/Thr isomerase
with a regulatory role on tau function, is known
to be a critical factor playing part in the AD
development. Pin1 converts cis to trans p-tau
whereby preventing pathogenic cis p231-tau
accumulation (cistauosis) and maintaining tau in a
trans conformation.[70]
Tau Aggregation
Insoluble tau deposits, resulting from tau mis-
folding and oligomerization, gradually accumu-
late in neurons, disrupt cell function, and initiate
neurodegeneration.[71] Two hexapeptide repeats,
amino acids 306–311 (PHF6, Val-Gln-Ile-Val-Lys-
Tyr, VQIVKY) and 317–335 (PHF6*, Val-Gln-Ile-Ile-
Lys-Tyr VQIINK), in the C-terminal region of tau
protein play a significant role in the formation of β-
sheets and fibrillary tangles.[6, 72, 73] PHF6, located
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at the beginning of the third MT-binding repeat, is
present in all tau isoforms, but PHF6* is located
at the beginning of the second MT-binding repeat.
It was observed that PHF6 and PHF6* can attach
to each other and form tau fibrillary tangles.[74]
Tau dimerization can occur by interaction between
two PHF6, two PHF6*, or between one PHF6 and
one PHF6* motif.[75] Finally, tau oligomers elon-
gate and form cross β-sheet structures, forming
the aggregates.[76] Although PHF6 and PHF6* are
prone to self-assembly, native tau under physiolog-
ical conditions is resistant to aggregation. Factors
enhancing the self-assembly of tau or neutralizing
its charge can induce tau aggregation. Due to the
presence of PHF6* encoded by exon 10, 4R tau iso-
forms are more prone to aggregation than 3R tau
isoforms.[77, 78] Mutations within the hexapeptide
motifs, such as the P301L tau mutation, promote
tau aggregation in patients with frontotemporal
dementia and parkinsonism linked to chromosome
17 (FTDP-17).[79] In addition to the tendency of exon
10 for aggregation, the N-terminal insert encoded
by exon 2 induces tau self-aggregation, whereas
the expression of exon 3 has an inhibitory role
on aggregation via a process modulated by the
expression of exon 10.[80] Also, deletion of the
positively charged Lys(K)280 residue can suppress
tau self-assembly.[74, 80]
It was demonstrated that anionic condens-
ing agents can induce tau aggregation. For
instance, heparin can bind to the second and
third MT-binding repeats, the flanking region, and
the N-terminal of tau protein, and induce tau
aggregation.[81, 82] Fatty acids, polyglutamic acid,
and tRNA, can also induce tau aggregation.[83] It
has been reported that preventing tau aggrega-
tion would rescue neurodegeneration. For exam-
ple, Curcumin, a tau aggregation inhibitor, effi-
ciently suppresses neurodegeneration in tauopa-
thy mouse models.
Pathogenic Role of Tau Protein in Neurode-
generative Diseases
In contrast to the normal physiological condition in
which tau has a stable and unfolded monomeric
conformation, in pathological conditions, tau
is phosphorylated or hyperphosphorylated
and self-aggregates, resulting in pathogenic
conformations in neurodegenerative diseases,
termed tauopathies.[7, 84] The roles of tau in
physiological and pathological conditions in the
cell are summarized in Figure 1.
Phosphorylation of tau at multiple residues
is characteristic of many neurodegenerative dis-
eases, which reduces the affinity of tau to
MTs, increases tau self-assembly,[85, 86] and finally
causes the formation of NFTs.[87, 88] The presence
of NFTs in specific regions of the brain disrupts
synaptic and neuronal communications, leads to
progression of memory loss, and produces a rapid
impairment of long-term potentiationwith induction
of toxic functions in the neurons.[43, 89]
Pathogenic forms of tau may spread in a prion-
like manner upon tauopathies, whose molecu-
lar mechanisms remain uncertain.[8, 90] Cell-to-cell
transmission of the tau aggregates causes neu-
ronal cell death and subsequent progression of
disease.[91, 92] In AD, this process follows a dis-
tinct pattern along the neuronal connections from
the entorhinal cortex to hippocampal areas and
further on through the limbic system.[93] In other
tauopathies, this process appears less hierarchical
throughout the brain.[93] Moreover, the localization
of tau inclusions is widely different in various
neurodegenerative diseases.[42, 94–96]
In addition to AD,[7] tau aggregates were
detected in a wide range of neurodegenerative
diseases including progressive supranuclear palsy
(PSP), corticobasal dementia, argyrophilic grain dis-
ease, Pick disease, Huntington disease, FTDP-17,
ALS, and Parkinson’s disease with dementia.[97, 98]
Unlike AD that has Aβ depositions in addition
to tauopathy, PSP is a relatively pure tauopa-
thy in which only tau deposits are seen. PSP
was shown to have shared polygenic heritability
with Parkinson’s disease and ALS, and most of
the corresponding genes were clustered around
chromosome 17.[99, 100] Interestingly, AD, primary
age related tauopathy (PART), and aging-related
tau astrogliopathy (ARTAG) are the predominant
sporadic tauopathies, in which oligodendrocytes
serve as targets for seeding and spreading patho-
logic tau proteins in the white matter.[101] Given
that the human retina lacks oligodendrocytes,
these cells may not be a component in the
pathogenesis of tauopathies in the eye. How-
ever, considering the presence of retinal microglial
cells and their role in engulfing tau oligomers
and induction of inflammation,[102] they may be
involved in tau seeding in retinal neurodegenera-
tions.
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Figure 1. Tau protein. (A) In physiological conditions, tau binds to microtubules by its microtubule binding domain in order to
stabilize microtubules for several cellular functions in the cells, such as axonal transportation. (B) In pathological conditions, tau is
phosphorylated or hyperphosphorylated (p-tau) by multiple kinases, leading to microtubule destabilization, pairing tau molecules
to each other, formation of toxic oligomers, and finally NFT formation.
Tau accumulation is also a result of trau-
matic brain injury (TBI) and chronic traumatic
encephalopathy (CTE), especially in sports that
repeatedly expose athletes to mild traumatic brain
injury (rmTBI) and in military personnel exposed to
repeated traumas.[103–105]
Mitochondrial dysfunction and reactive oxy-
gen species (ROS) production can induce tau
hyperphosphorylation.[106] It has been demon-
strated that hyperphosphorylated tau reduces the
release of cytochrome C from mitochondria as well
as caspase-9 and caspase-3 activity, and protects
cells from apoptosis.[107] Moreover, tau via stabi-
lizing β-catenin and increasing its nuclear translo-
cation has the ability to antagonize apoptosis and
promote cell survival.[107, 108] Tau hyperphospho-
rylation confers cellular resistance to chemically
induced apoptosis through upregulated glycogen
synthase kinase-3β (GSK3β) and preserving β-
catenin.[108]
Tau overexpression causes vascular changes
in the cerebral cortex that are accompanied
by cortical atrophy. This overexpression in the
neurons can lead to dramatic cell-nonautonomous
changes in cerebral endothelial cells, alter
the integrity of the cerebral microvasculature,
and induce neurodegeneration related to
vascular abnormalities.[109] A similar situation
occurs in AMD, where dramatic neovascular
changes accompany neurodegeneration.[110]
Additionally, tau overexpression would result
in impaired axonal transport, leading to
neurodegeneration.
All six tau isoforms are expressed in both soluble
and insoluble tau isolates in patients with CTE
and CTE-ALS. The expression of oligomerized tau
protein and activated GSK3β, pThr175 tau, and
pThr231 tau were observed in hippocampal neurons
and spinal motor neurons. Phosphorylation of tau
at Thr175 and Thr231 and activation of GSK3β are
reported features of tauopathy in CTE and CTE-
ALS.[111]
A direct association has been proposed
between Aβ toxicity and tau pathology.[112, 113] High
levels of Aβ in transgenic mice overexpressing
amyloid precursor protein (APP) accelerated tau
phosphorylation. Intracerebral injection of Aβ into
tau transgenic mice augmented pathogenic
conditions.[114, 115] Moreover, pathogenic tau
augments the secretion of α-synuclein and induces
its toxicity by promoting smaller α-synuclein
inclusion formation in human neuroglioma cells.[116]
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It was also shown that α-synuclein can induce tau
phosphorylation.[117, 118]
Cistauosis is a mechanism that occurs before
insoluble tau deposition and within days after TBI.
Cis p-tau is a pathogenic form of tau protein that
is prominently formed in human CTE and uses
a prion-like mechanism for its spreading in the
brain. Inhibition of cis p-tau by monoclonal anti-
bodies was reported to decrease cellular neuro-
toxicity, histopathological changes, and behavioral
deficits. Cis p-tau is present in cortical axons and
cerebrospinal fluid of human TBI and positively
correlates with axonal injury. Therefore, antibod-
ies that target this pathogenic form of tau are
potential novel treatments for neurodegenerative
diseases.[70]
Tau Isoform Pathology
4R tau isoforms include a fourth MT-binding repeat
encoded by exon 10, whereas the 3R tau isoform
mRNAs lacks exon 10. The majority of mutations
occur in exon 10 or close by. Approximately 40
pathogenic mutations in the MAPT gene have
been identified, most of them are associated with
clinical signs of FTDP-17 with degeneration in
the frontotemporal lobar regions.[119] Tau mutations
affecting splicing efficacy are located either in exon
10 or intron 10 and result in a change of the 4R/3R
tau mRNA ratio.[120, 121]
All six tau isoforms and tau tangles in the brain
of AD patients are formed from both 3R and
4R isoforms with equal ratio, similar to healthy
adults;[122–124] however, a higher ratio of 4R/3R was
observed in PSP in comparison to AD patients and
healthy adults.[124, 125] Moreover, there have been
several cases of PSP and frontotemporal lobar
degeneration (FTLD) that had higher 4R tau/3R tau
isoforms than FTDP-17 cases.[124]
Tau Protein in Inflammation
Pathogenic tau molecules, by attaching to each
other, form large fibrillar molecules known as
tangles. However, there is evidence to sug-
gest that smaller soluble aggregates, named
oligomers are the most toxic species and are
formed prior to the tangles.[126, 127] Tau oligomers
may induce inflammatory signaling in the brain
of patients with FTLD, AD, and other neu-
rodegenerative diseases. These toxic oligomers
are associated with neuroinflammation markers
suggesting their role in chronic neuroinflamma-
tion, physiological impairments, cellular dysfunc-
tion, and ultimately, neurodegeneration.[128–130]
Oligomers co-localize with astrocytes, microglia,
pro-inflammatory cytokines, and high mobility
group box-1 protein (HMGB1). Moreover, astrocytes
interact with tau oligomers but do not engulf
them, while microglia[130] can engulf tau oligomers,
secrete them by exosomes, facilitate their propa-
gation, and induce inflammation.[102] Therefore, tau
oligomers augment inflammation and cause more
damage to cells, which may increase oligomer
formation.[130]
In addition, in animal models of tauopathy, tau
oligomers were detected to be associated with
inflammatory cells in the retina, suggesting that the
retina can be a valid and non-invasive biomarker
for brain degenerative pathologies.[130] It is notable
that tau aggregates would induce ROS, resulting
in inflammation in the CNS of those tauopathy
patients.
Pathogenic Role of p-tau in Ocular Neurode-
generative Diseases
The retina is a part of the CNS, containing various
cell types, including photoreceptors, horizontal
cells, amacrine cells, bipolar cells, and retinal
ganglion cells (RGCs), and is easily accessible to
noninvasive imaging techniques, such as scanning
laser ophthalmoscopy (SLO) and optical coherence
tomography (OCT). Identifying retinal pathological
changes with these techniques may be used as
potential biomarkers for AD,[131] and therefore, ocu-
lar screening programs can be planned for identify-
ing tauopathies such as AD.[132] Although the sensi-
tivity and specificity of non-retinal biomarkers has
been determined in brain neurodegeneration,[133]
there has been no report on the sensitivity and
specificity of retinal biomarkers for ocular and brain
neurodegenerative disorders. Although there are
reports demonstrating tau hyperphosphorylation
and aggregation in ocular neurodegeneration, the
actual tau pathogenicity upon the disease has not
been extensively studied thus far.[131] And so, it
seems difficult to clearly demonstrate the superi-
ority of the pathologic form of tau as a marker in
conventional behavioral tests and neuroimaging.
Some of the pathological changes in AD patients
include reduced thickness of the retinal nerve
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fiber layer (NFL), attenuation in retinal blood flow
and venous diameter, axonal degeneration in
optic nerves, decreased number of RGCs, and
astrocytosis.[134–137] Moreover, reduction of macular
thickness is inversely associated with the severity
of AD.[138] There is a higher incidence of AMD in
patients with AD;[139] therefore, there is an strong
correlation between AMD and AD incidence and
the retinal changes can be used as potential
biomarkers for the diagnosis of cerebral neurode-
generative diseases.[136, 140] Retinal degeneration in
AD was triggered by a pathogenic form of tau via
calpain-mediated tau hyperphosphorylation.[44]
The presence of tau inclusions in human reti-
nas was discovered for the first time in the
corpora amylacea of the optic nerve and the
retina.[141] Pathogenic forms of tau in the form
of oligomers or aggregations were detected in
a variety of ocular disorders such as AMD and
glaucoma. Tau was detected in various sublayers
of the retina including the inner nuclear layer
(INL), inner/outer plexiform layer, and NFL of the
retinas from patients with AMD.[142] AMD, one of
the leading causes of blindness worldwide,[143]
is a complex age-related pathology that occurs
as an interplay between oxidative stress, low-
grade inflammation, and aberrant accumulations
of extracellular protein molecules.[144] Induction
of neuroinflammation[130] and aggregation of tau
proteins within retinal layers of cases with age-
related retinal lesions[145] are two main methods
by which tauopathy can act in the pathogenesis
of AMD. Additionally, correlations between AD
and glaucoma have been well documented.[146]
P-tau plays a pathogenic role in the develop-
ment of glaucomatous optic neuropathy and is
upregulated in the retrolaminar region of the optic
nerve head in glaucomatous eyes.[147] Moreover,
mislocalization of p-tau aggregates was detected
in the somatodendritic compartments of RGCs that
were subjected to high intraocular pressure.[147]
Importantly, tau knock-down using a targeted
siRNA protected RGC somas and axons from
hypertension-induced damage.[148] Tau oligomers
were detected in the retina of an animal model of
glaucoma and it was observed that tau inhibition
could reduce retinal degeneration.[148] Moreover, it
was demonstrated that calpains, proteins belong-
ing to a family of calcium-dependent and non-
lysosomal cysteine proteases are activated after
ocular hypertension, a condition in which increase
of calcium in the retinas and increase of calpain-
dependent proteolysis of tau occurs that leads
to neuronal cell death.[149, 150] It is noteworthy
that augmentation of hyperphosphorylated tau has
been identified in the vitreous samples of dia-
betic retinopathies that represent a form of ocular
degeneration.[151]
AT8 tau with phosphorylation profile at Ser202
and Thr205 has been well characterized, and AT8
antibody was used to stage human neuropatho-
logical diseases.[152] AT8 hyperphosphorylated tau
was detected in the outer border of the INL and
specifically in the inner plexiform layer (IPL) of
glaucomatous retinas. In addition, this form of tau
colocalizes with parvalbumin in the retinal horizon-
tal cells.[153] AT8 tau protein was also detected with
Aβ depositions in various retinal layers including
the RGC layer, IPL, INL, outer plexiform layer (OPL),
and outer nuclear layer (ONL) in Tg2576 mice.[154]
Photoreceptor cells have high energy demands
and are significantly affected by ageing.[155, 156] Tau
aggregates were observed within the cytoplasm
of rod and cone photoreceptors, and a positive
correlation was observed between age and the
number of inclusions in these cells.[145] Conversely,
p-tau is specifically accumulated in primate cones
while reducing the cellular functions.[12] Diffuse tau
aggregates were found in the retinal INL of enucle-
ated eyes that had abnormal retinal changes. They
were also detected in the cytoplasm of several
photoreceptor cells in patients older than 63 years,
and a positive correlation was observed between
the patients’ age and the numbers of RGCs with
tau aggregates. In addition, aggregated tau was
found within the cytoplasm of photoreceptor cells
in the majority of patients above 63 years of
age.[145] OA, one of the positive regulators of p-
tau accumulation, was shown to have a destructive
role in the cytoskeleton network and growth-cone
cells.[157]
Transgenic mice expressing P301S mutant
human tau model tauopathy develop
hyperphosphorylated tau aggregations in the
CNS. P301S mutant tau carries a substitution of Ser
instead of Pro in exon 10 of the MAPT gene.[158] In
P301S retinas, hyperphosphorylated tau molecules
are aggregated in the nerve fiber and RGC layers.
Also, RGC axonal outgrowth did not respond to
neurotrophic stimuli in retinal explants cultured
from P301S mice, suggesting that pathogenic tau
can change neurotrophic signaling.[159] Moreover,
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the mild tauopathy that developed in RGCs of
P301S mice induced functional retinal changes
and neuronal dysfunction by disrupting brain-
derived neurotrophic factor (BDNF) signaling, via
the TrkB receptor that is essential for neuronal
survival and synaptic plasticity.[160] Moreover,
P301S tau aggregates in RGCs were associated
with a reduction in anterograde and retrograde
axonal transport in vivo, with a markedly increased
effect of excitotoxic injury.[161]
Another tau gene mutation is P301L that
expresses Leu instead of Pro at position 301 in both
the shortest and longest four repeat tau isoforms,
and forms NFTs in the CNS.[162] Age-related neu-
rodegenerative changes with significant reduced
thickness of retinal INL were observed in P301L
mice, and these changes were more pronounced
at the peripheral areas and with increasing age.
Furthermore, an increase in the size of the RGCs
obtained from tau P301L mice was observed with
increasing age, in contrast to control mice in which
RGC sizes decreased with increasing age.[163]
The dynactin complex plays a pivotal role in
the transportation network in many cell types
by mediating the binding of MT motor complex
dynein to its cargoes.[164] Tau and dynactin have
extensive interactions, and dynactin attachment to
MTs is facilitated by the binding of tau N-terminal
domain to the C-terminus of the p150 subunit of
dynactin.[28] Mutation in the arginine residue in the
N-terminal domain of tau was detected in patients
with FTDP-17 that affects tau binding to dynactin,
and tau was abnormally distributed in the RGC
axons of tau P301S transgenic mice.[28] However,
recombinant human tau promoted the attachment
of the dynactin complex to axonal microtubules,
which indicates a potential role of tau in axonal
transportation.[28]
Transportation of organelles such as mitochon-
dria and peroxisomes by kinesin molecules was
inhibited in rat RGCs with abnormally aggregated
tau, evidencing the essential role of tau in kinesin-
mediated transportation. Thus, rat RGCs with accu-
mulated tau suffered from loss of energy produc-
tion and accumulation of ROS due to perturbation
of mitochondria and peroxisome function. More-
over, the rate of anterograde transportation that
include vesicles necessary for growth cones and
synaptic function was slower.[165]
Oxidative damage was shown to be associ-
ated with death of cones in retinitis pigmentosa,
and of both photoreceptor cell types, in AMD.[166]
Thioredoxin 1 (TRX1) in the retina plays a protec-
tive role against photooxidative damage.[167] Rod-
derived cone viability factor (RdCVF) is a member
of the thioredoxins family[168] and a trophic factor
secreted by rods for maintaining cone viability
and functionality.[169] In murine models, RdCVF is
encoded by the Nxnl1 gene that also encodes
for a second polypeptide, RdCVFL, by alterna-
tive splicing. RdCVFL inhibits tau phosphoryla-
tion and protects tau from oxidative damage.[170]
Upregulation of tau phosphorylation has been well
demonstrated in the retinas of Nxnl1-/- mice.[171, 172]
Therefore, therapeutic modalities augmenting the
NXNL1 gene or the corresponding protein may be
promising for the treatment of cerebral and ocular
neurodegeneration.
Therapeutic Strategies for Targeting Patho-
logic Tau
The pathogenic tau molecule is an excellent thera-
peutic target for neurodegenerative diseases using
several strategies such as reducing levels, altering
post-translational modifications, or blocking prop-
agation of pathogenic tau.
Several tauopathy-based targeted therapies
for neurodegenerative diseases have been
introduced, such as suppressing tau misfolding,[173]
targeting tau acetylation,[174] inhibiting tau-
induced proteasome impairment,[175] and tau
immunotherapy.[176–180] Several therapeutic
modalities for inhibiting tau aggregation have
been reported,[19, 181] among which, the use of small
molecules has recently gained much interest.
Several small molecules exhibit anti-tau
aggregation properties;[182, 183] one of these is
D-enantiomeric peptides that has modulating
mechanisms on tau self-aggregation.[184] Other
small molecules that were shown to have anti-
tau aggregation effects have an eight amino
acid peptide named NAP (Davunetide).[185]
Clinically, NAP (davunetide) exhibited its efficacy
in prodromal AD patients that had equal 3R and
4R Tau isoforms but not in the PSP cases that had
increased 4R Tau.[186] Cationic small molecules
and cationic osmolyte urea also have inhibitory
effects on tau accumulation.[187–189] Moreover,
the inhibitory effect of a cationic polymer
polyethyleneimine and a cationic polypeptide
arginine on the aggregation of VQIVYK and
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GKVQIINKLDL peptides in tau protein was also
observed.[190]
Antisense oligonucleotides are other small
molecules that selectively downregulate human
tau at mRNA and protein levels in adult mouse
brain that express mutant P301S human tau.[191]
Moreover, the chaperone Artemin was found to
be an effective inhibitor of tau inclusions in both
physiologic and supraphysiologic concentrations,
in a dose-dependent manner and in a cell-free
model system. This supports the idea that Artemin
can be a therapeutic option for people with AD.[192]
Although several specific small molecules for
targeting pathogenic tau have been discovered,
more studies are needed to illustrate the safety and
efficacy of these molecules as novel drugs. More
importantly, it is of crucial importance to clarify
which epitope to target?
We herein studied latest reports on tau
pathology; especially in ocular neurodegeneration.
Although we may not clearly describe the
pathogenic tau species playing part in ocular
neurodegeneration, however, due to similarities
between brain and eye neurodegeneration,
the aforementioned treatment modalities
for brain tauopathies sound like efficient
therapeutic strategies in fighting with the ocular
neurodegeneration.
Summary
The current review, based on numerous studies
on the role of pathogenic tau in neurodegenera-
tion, attempts to highlight the connection between
brain and eye diseases. Pathogenic tau protein
exerts destructive effects that are associated with
cerebral degenerations such as AD, PSP, and TBI,
and ocular neurodegenerative disorders such as
AMD, glaucoma/ocular hypertension, and probably
diabetic retinopathy. The destructive effects of
the pathogenic form of tau can be exerted by
several forms of tau such as soluble oligomers,
insoluble aggregates, or even by cis p-tau which
is an early driver of pathogenic tau. Consider-
ing this evidence, targeted therapy based on
pathogenic tau could be a promising therapeutic
for patients with CNS or ocular neurodegeneration,
to not only prevent the more destructive effects of
pathogenic tau, but also restore normal functioning
to neural cells. Moreover, with the identification of
tauopathy-related retinal changes with noninvasive
imaging techniques, screening programs for the
early diagnosis of CNS tauopathies such as AD can
be planned.
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